Nanobiotix S.A. ADR (NBTX): Price and Financial Metrics
NBTX Price/Volume Stats
| Current price | $5.41 | 52-week high | $11.00 |
| Prev. close | $5.50 | 52-week low | $1.75 |
| Day low | $5.20 | Volume | 1,500 |
| Day high | $5.55 | Avg. volume | 34,279 |
| 50-day MA | $6.47 | Dividend yield | N/A |
| 200-day MA | $7.15 | Market Cap | 254.99M |
NBTX Stock Price Chart Interactive Chart >
Nanobiotix S.A. ADR (NBTX) Company Bio
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
Latest NBTX News From Around the Web
Below are the latest news stories about NANOBIOTIX SA that investors may wish to consider to help them evaluate NBTX as an investment opportunity.
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian MarketsPARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize |
Voting Rights and Shares Capital of the CompanyIn accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares Outstanding1Total number of voting rightsTotal voting rights, theoretical2Total voting rights,exercisabl |
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities |
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR316.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline Study 102 Phase 1 data in head and neck cancer strengthens hypotheses for pivotal NANORAY-312 trial designPromising initial anti-tumor efficacy, median overall survival (mOS) of 23 months, 92% local disease con |
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ETPARIS and CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, a |
NBTX Price Returns
| 1-mo | -16.77% |
| 3-mo | -27.48% |
| 6-mo | -13.99% |
| 1-year | N/A |
| 3-year | -66.35% |
| 5-year | N/A |
| YTD | -25.69% |
| 2023 | 98.37% |
| 2022 | -54.69% |
| 2021 | -50.91% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...